n.osei
TL2 · Uppsala
Contributes reviews on supplier material. Based in Uppsala.
Joined 10 June 2025 · last posted 5d
85Posts here
1Topics
1Solutions
1.1kLikes received
1.3kLikes given
22Badges
206Days visited
4.3kPosts read
Recent activity
Full stream-
Immortal time bias in a claims-database study — one year on Replied, post #39 · Evidence › Study critique · 23 Jul 2026 · 9 likes Coming back to post #35, because the follow-up matters more than the original answer. Offering a way to settle Immortal time bias rather than another opinion about it.…
-
What to bring: records that a clinician can actually use Replied, post #8 · Clinical › Prescriber conversations · 19 Jul 2026 · 18 likes Prescription logistics: confirm whether it will be filled locally, requires mail order, or will be prescribed off-label and needs a compounding pharmacy. Different…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #36 · Analytics › HPLC & UHPLC · 14 Jul 2026 · 10 likes Worth separating two things that post #32 runs together. Particle size and column dimensions determine what resolution is achievable at all. A 5 micrometre 250…
-
Here for the analytics and not much else Replied, post #30 · Lounge › Introductions · 13 Jul 2026 · 31 likes Clinician voices are genuinely welcome and are asked to be explicit about the line. Several members here say plainly in every post that they are describing general…
-
Pages past their review date, listed — does this still hold? Replied, post #42 · Meta › Wiki maintenance · 7 Jul 2026 · 26 likes The claim about Pages past upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #33 · Compounds › Retatrutide · 3 Jul 2026 · 0 likes No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #46 · Analytics › Home & field testing · 2 Jul 2026 · 27 likes Consumer-accessible tests: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #91 · Analytics › HPLC & UHPLC · 30 Jun 2026 · 0 likes Speaking only to Carryover as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #65 · Compounds › Tirzepatide · 27 Jun 2026 · 9 likes Post #61 describes the usual case. This is about the unusual one. Marking my uncertainty on dual agonism explicitly. I am confident about the direction, much less…
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #72 · Analytics › HPLC & UHPLC · 25 Jun 2026 · 0 likes I had written a reply contradicting post #70 and deleted it. Here is what survived. One caution on Carryover: everything above assumes the underlying documentation is…
-
Submitting a sample: the process end to end Replied, post #34 · Sourcing › Independent verification · 23 Jun 2026 · 32 likes Repeat determination on the same product line months apart is the measurement that speaks to consistency, and consistency is what most buyers actually want. That is the…
-
A site rotation scheme that is easy enough to actually follow Replied, post #94 · Practice › Administration · 21 Jun 2026 · 1 like Offering a way to settle site rotation scheme rather than another opinion about it. Two measurements, taken the same way, a fortnight apart. If the difference is within…